Genmab Reports Positive Rina-S Data in Platinum-Resistant Ovarian Cancer
Genmab reports a 45.9% response rate and 12.1-month response duration for Rina-S in platinum-resistant ovarian cancer. Data, safety and what is next.
Tag: Rinatabart Sesutecan
Read More